home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410o.zip
/
M94A2856.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
2KB
|
40 lines
Document 2856
DOCN M94A2856
TI Triple combination therapy of Foscarnet.
DT 9412
AU Convey P; Scolaro M; Brucker R
SO Int Conf AIDS. 1994 Aug 7-12;10(1):209 (abstract no. PB0267). Unique
Identifier : AIDSLINE ICA10/94369719
AB OBJECTIVE: To evaluate the efficacy of Foscarnet, a non-nucleoside HIV-1
reverse transcriptase inhibitor, given in combination with 2 nucleoside
HIV reverse transcriptase inhibitors on immunological and virological
markers. METHOD. Foscarnet was given intravenously (90 mg/kg every 12
hours as an induction for 30 days, followed by a maintenance dose of 90
mg/kg every 24 hours for 40-70 days), in combination with the nucleoside
HIV-1 reverse transcriptase inhibitors zidovudine (300-600 mg/daily),
and either dideoxyinosine (400-600 mg/daily based on kilogram weight) or
dideoxycytidine (0.75-2.25 mg/daily) to 18 HIV-1 positive male patients
with mean CD4 cell count (45 +/- 20), who had been given nucleoside
HIV-1 inhibitors for 8-16 weeks prior to combination therapy. RESULTS:
Patients with p24 antigenemia (14/18) showed a transient decline (30% to
85%) in serum p24 concentration after the start of combination therapy
with a gradual return to baseline levels before the end of the therapy
regimen. Significant changes in CD4, CD8, B, NK cell, and B-2
microglobulin levels were not observed during the course or after
combination therapy. Hematologic and renal toxicities were observed.
These were transient and resolved by dosage adjustment. CONCLUSION:
Foscarnet in combination with AZT and DDI or DDC resulted in
significant, though transient, reduction of p24 antigenemia.
DE Bone Marrow Diseases/CHEMICALLY INDUCED Comparative Study
Foscarnet/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/*THERAPEUTIC USE
Human HIV Core Protein p24/BLOOD HIV-1/*DRUG EFFECTS Kidney
Diseases/CHEMICALLY INDUCED Reverse Transcriptase/*ANTAGONISTS & INHIB
Treatment Outcome Viremia/DRUG THERAPY Zalcitabine/ADMINISTRATION &
DOSAGE/ADVERSE EFFECTS/*THERAPEUTIC USE Zidovudine/ADMINISTRATION &
DOSAGE/ADVERSE EFFECTS/*THERAPEUTIC USE CLINICAL TRIAL MEETING
ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).